To the Editor.—
Thymostimulin (TMS), a calf thymus extract, can be successfully used in the treatment of patients with viral diseases and cell-mediated immune defects. A significant reduction in the number of total circulating T lymphocytes has been observed in patients with psoriasis, while the number of circulating B cells was normal and there was an increase of null cells.1 In skin, the dermal mononuclear infiltrate consists almost exclusively of T lymphocytes and macrophages.2Recently, Baker et al3 studied the relationship between T-cell populations in blood and in skin of psoriatic patients as well as the correlation with the chronicity, type, and extent of the skin lesions. In blood from patients with guttate psoriasis (GP), the reduction in the number of T lymphocytes was due entirely to a decrease in T helper-inducer (Th) cells. In chronic plaque (CP) psoriasis, both Th and suppressor-cytotoxic T-lymphocyte (Ts) subset were
Pedragosa R, Vidal J. Thymostimulin in Treatment of Psoriasis. Arch Dermatol. 1986;122(6):624. doi:10.1001/archderm.1986.01660180024004
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: